Zosano Pharma Corporation [NASDAQ: ZSAN] stock went on a downward path that fall over -7.20% on Thursday, amounting to a one-week price increase of more than 35.58%. The company report on November 13, 2020 that Lawsuits Filed Against WFC, ZSAN and ICPT – Jakubowitz Law Pursues Shareholders Claims.
Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Wells Fargo & Company (NYSE:WFC).
Over the last 12 months, ZSAN stock dropped by -77.14%. The average equity rating for ZSAN stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $37.71 million, with 95.62 million shares outstanding and 68.49 million shares in the current float. Compared to the average trading volume of 6.42M shares, ZSAN stock reached a trading volume of 4095126 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Zosano Pharma Corporation [ZSAN]:
Maxim Group have made an estimate for Zosano Pharma Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 17, 2019. While these analysts kept the previous recommendation, Piper Jaffray raised their target price to Overweight. The new note on the price target was released on March 24, 2017, representing the official price target for Zosano Pharma Corporation stock. On November 11, 2015, analysts decreased their price target for ZSAN shares from 11 to 7.
The Average True Range (ATR) for Zosano Pharma Corporation is set at 0.06 The Price to Book ratio for the last quarter was 1.37.
ZSAN Stock Performance Analysis:
Zosano Pharma Corporation [ZSAN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 35.58. With this latest performance, ZSAN shares dropped by -29.35% in over the last four-week period, additionally sinking by -44.50% over the last 6 months – not to mention a drop of -77.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZSAN stock in for the last two-week period is set at 35.24, with the RSI for the last a single of trading hit 48.12, and the three-weeks RSI is set at 36.73 for Zosano Pharma Corporation [ZSAN]. The present Moving Average for the last 50 days of trading for this stock 0.9424, while it was recorded at 0.4397 for the last single week of trading, and 0.9126 for the last 200 days.
Insight into Zosano Pharma Corporation Fundamentals:
Return on Total Capital for ZSAN is now -141.21, given the latest momentum, and Return on Invested Capital for the company is -168.41. Return on Equity for this stock declined to -267.52, with Return on Assets sitting at -102.35. When it comes to the capital structure of this company, Zosano Pharma Corporation [ZSAN] has a Total Debt to Total Equity ratio set at 189.02. Additionally, ZSAN Total Debt to Total Capital is recorded at 65.40, with Total Debt to Total Assets ending up at 47.13. Long-Term Debt to Equity for the company is recorded at 128.20, with the Long-Term Debt to Total Capital now at 44.36.
Reflecting on the efficiency of the workforce at the company, Zosano Pharma Corporation [ZSAN] managed to generate an average of -$671,232 per employee.Zosano Pharma Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.
ZSAN Stock EPS
With the latest financial reports released by the company, Zosano Pharma Corporation posted -0.55/share EPS, while the average EPS was predicted by analysts to be reported at -0.58/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZSAN.
Zosano Pharma Corporation [ZSAN] Insider Position Details
There are presently around $4 million, or 12.50% of ZSAN stock, in the hands of institutional investors. The top three institutional holders of ZSAN stocks are: AISLING CAPITAL MANAGEMENT LP with ownership of 2,718,226, which is approximately 0% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 1,396,756 shares of the stock with an approximate value of $0.65 million in ZSAN stocks shares; and BLACKROCK INC., currently with $0.51 million in ZSAN stock with ownership of nearly 91.991% of the company’s market capitalization.
Positions in Zosano Pharma Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 24 institutional holders increased their position in Zosano Pharma Corporation [NASDAQ:ZSAN] by around 2,006,668 shares. Additionally, 9 investors decreased positions by around 2,881,058 shares, while 10 investors held positions by with 3,645,035 shares. The mentioned changes placed institutional holdings at 8,532,761 shares, according to the latest SEC report filing. ZSAN stock had 12 new institutional investments in for a total of 598,019 shares, while 5 institutional investors sold positions of 299,232 shares during the same period.